Results 81 to 90 of about 45,621 (284)

Clinical applications of pharmacogenomics [PDF]

, 2017
Indexación: Scopus.Pharmacogenomics is an emergent field aimed at tailoring pharmacological therapy. Genetic polymorphisms can modify the expression and function of enzymes and proteins involved in drug metabolism, affecting absorption, distribution ...
Cayún, J.P., Escalante, P., Gallegos, B., Lares-Asseff, I., Meneses, F., Miranda, C., Quiñones, L., Roco, Á., Varela, N., Zaruma-Torres, F.   +9 more
core   +1 more source

The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors

Pharmacogenomics and Personalized Medicine, 2015
DA Sychev,1,2 NP Denisenko,1,2 ZM Sizova,2 AV Grachev,3 KA Velikolug4 1Russian Medical Academy of Post-Graduate Education, 2I.M. Sechenov First Moscow State Medical University, 3SM-Clinic, 4Out-patient department Number 51 branch 3, Moscow, Russia ...
Sychev DA, Denisenko NP, Sizova ZM, Grachev AV, Velikolug KA   +4 more
doaj  

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective.
Cinzia Dello Russo, Iain Frater, Rebecca Kuruvilla, Stefanie Lip, Hannah O'Neill, Kerry Burke, Vicky Chaplin, Alexander S. F. Doney, Salim Elyas, Nicholas Greaves, Sophie Harding, David Hargroves, Judith Hayward, Dyfrig A. Hughes, Tom A. T. Hughes, Sree Kondapally, Patrick Mok, Aaron Peace, Imran Rafi, Simon Ray, Vicky Stinton, Luigi Venetucci, Munir Pirmohamed   +22 more
wiley   +1 more source

Efficacy of H. pylori eradication depending on genetic polymorphism of CYP2C19, MDR1 and IL-1β [PDF]

Терапевтический архив, 2019
Aim. To evaluate an association of genetic polymorphisms CYP2C19, MDR1, and IL-1β on the eradication rate by 10-day modified therapy in patients with H. pylori - associated diseases. Materials and methods.
N V Bakulina, I V Maev, I V Savilova, I G Bakulin, T A Il'chishina, K A Zagorodnikova, A A Murzina, D N Andreev   +7 more
doaj   +1 more source

Metabolism of profenofos to 4-bromo-2-chlorophenol, a specific and sensitive exposure biomarker. [PDF]

, 2013
Profenofos is a direct acting phosphorothioate organophosphorus (OP) pesticide capable of inhibiting β-esterases such as acetylcholinesterase, butyrylcholinesterase, and carboxylesterase.
Chi, Lai-Har, Dadson, Oswald A, Ellison, Corie A, Farahat, Fayssal M, Farahat, Taghreed, Lein, Pamela J, McGarrigle, Barbara P, Olson, James R, Singleton, Steven T   +8 more
core   +1 more source

Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: Effects on clopidogrel response

Indian Heart Journal, 2013
Aims/objective: Influence of genetic variations on the response of clopidogrel, an antiplatelet drug is implicated. In the present study, the prevalence of single nucleotide polymorphisms of MDR1 (C3435T), CYP2C19 [CYP2C19*2 CYP2C19*3, CYP2C19*17] and ...
Kavita K. Shalia, Vinod K. Shah, Poonam Pawar, Siddhi S. Divekar, Satchidanand Payannavar   +4 more
doaj   +1 more source

Association of CYP2C19*2 polymorphisms and high on-treatment platelet reactivity in acute myocardial infarction or coronary artery in-stent restenosis patients during dual antiplatelet therapy

Medicine in Drug Discovery, 2020
Objective: Cytochrome CYP2C19 mutant allele is associated with high on-treatment platelet reactivity (HTPR) after standard clopidogrel treatment, which is accompanied by an increased risk of ischemic events. This study assesses the association of CYP2C19
Yawei Yang, Wei Zhang, Pan Li, Ying Gu, Liping Ma, Min Fan   +5 more
doaj   +1 more source

Modulating effect of Cu(II) complexes with enamine and tetrazole derivatives on CYP2C and CYP3A and their cytotoxic and antiproliferative properties in HepG2 spheroids

Acta Biomedica Scientifica, 2022
CYP2C and CYP3A cytochromes are induced by a variety of compounds and affect the pharmacokinetics and pharmacodynamics of a large number of drugs. Currently, the possibility of using copper coordination compounds in antitumor therapy is being actively ...
L. S. Klyushova, Yu. A. Golubeva, V. A. Vavilin, A. Yu. Grishanova   +3 more
doaj   +1 more source

Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention

Clinical pharmacology and therapy, 2020
Genotyping for CYP2C19 no function alleles to guide antiplatelet therapy after percutaneous coronary intervention (PCI) improves clinical outcomes. Although results for the increased function CYP2C19*17 allele are also reported, its clinical relevance in
Craig R. Lee, Cameron D Thomas, A. Beitelshees, S. Tuteja, P. Empey, James C. Lee, N. Limdi, Julio D. Duarte, T. Skaar, Yiqing Chen, Kelsey J Cook, James C. Coons, C. Dillon, Francesco Franchi, Jay Giri, Y. Gong, R. Kreutz, C. McDonough, J. Stevenson, K. Weck, D. Angiolillo, Julie A. Johnson, G. Stouffer, L. Cavallari   +23 more
semanticscholar   +1 more source

The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping [PDF]

Pharmacogenetics and Genomics, 2014
The polymorphic hepatic enzyme CYP2C19 catalyzes the metabolism of clinically important drugs such as clopidogrel, proton-pump inhibitors, and others and clinical pharmacogenetic testing for clopidogrel is increasingly common. The CYP2C19*10 single-nucleotide polymorphism (SNP) is located 1 bp upstream the CYP2C19*2 SNP.
Taimour Y, Langaee, Hao-Jie, Zhu, Xinwen, Wang, Nihal, El Rouby, John S, Markowitz, Joyce A, Goldstein, Julie A, Johnson   +6 more
openaire   +2 more sources